Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0TTCXD
ADC Name
CN105828840B ADC-123
Synonyms
CN105828840B ADC-123
   Click to Show/Hide
Organization
Genentech Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Drug-to-Antibody Ratio
1.9
Antibody Name
CN105828840B_ADC-123 antibody
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
CN105828840B_ADC-123 linker
General Information of The Activity Data Related to This ADC
Obtained from the Model Organism Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI) 
≍ 16.7
%
Breast cancer model MMTV-HER2 Fo5
Tumor Growth Inhibition value (TGI) 
≍ 94.7
%
Breast cancer model MMTV-HER2 Fo5
Full List of Activity Data of This Antibody-drug Conjugate
Obtained from the Model Organism Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≍ 16.70% (Day 14) High HER2 expression (HER2 +++)
Method Description
Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≍ 94.70% (Day 14) High HER2 expression (HER2 +++)
Method Description
Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model Breast cancer model MMTV-HER2 Fo5
References
Ref 1 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.